Publications by authors named "Heather Poad"

Claim this Profile
I
Individual participant data from digital sources informed and improved precision in the evaluation of predictive biomarkers in Bayesian network meta-analysis.
Chinyereugo M Umemneku-Chikere, Lorna Wheaton, Heather Poad, Devleena Ray, Ilse Cuevas Andrade

J Clin Epidemiol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status.
Heather Poad, Sam Khan, Lorna Wheaton, Anne Thomas, Michael Sweeting

Cancers (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.
James W F Catto, Kathryn Gordon, Michelle Collinson, Heather Poad, Maureen Twiddy

J Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).
Irene J Higginson, Andrew Wilcock, Miriam J Johnson, Sabrina Bajwah, Natasha Lovell, Heather Poad

Thorax· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Hannah L Buckley, Fiona J Collinson, Gemma Ainsworth, Heather Poad, Louise Flanagan

BMC Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study.
Jamie B Oughton, Heather Poad, Maureen Twiddy, Michelle Collinson, Victoria Hiley

BMJ Open· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis